Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2025
0mins
Should l Buy HIMS?
Source: NASDAQ.COM
Hims & Hers Health Performance: Hims & Hers stock surged 11.2% after reporting a sales beat with a 111% year-over-year increase, despite an earnings miss of $0.20 per share compared to the expected $0.23. The company forecasts continued growth, projecting sales between $2.3 billion and $2.4 billion for the year.
Impact on Competitors: The positive outlook for Hims & Hers is seen as a competitive threat to larger drugmakers like Eli Lilly and Novo Nordisk, whose stocks fell by 3.2% following the news, indicating concerns about sharing future profits in the GLP-1 market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 24.290
Low
16.50
Averages
32.95
High
60.00
Current: 24.290
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Q4 Earnings Overview for Healthcare Tech Stocks
- Hims & Hers Performance: Hims & Hers Health reported revenues of $617.8 million, a 28.4% year-over-year increase, but while the full-year revenue guidance exceeded expectations, the next quarter's guidance fell significantly short, indicating market caution regarding future growth.
- Privia Health Strong Growth: Privia Health achieved revenues of $541.2 million, up 17.4% year-over-year, outperforming analyst expectations by 4.8%, with strong full-year revenue guidance reflecting its competitiveness and market recognition in the healthcare technology sector.
- GoodRx Revenue Decline: GoodRx reported revenues of $194.8 million, down 1.9% year-over-year, exceeding analyst expectations, yet the full-year revenue and EBITDA guidance significantly missed expectations, leading to a 5.7% drop in stock price, highlighting market challenges.
- Tandem Diabetes Stable Performance: Tandem Diabetes reported revenues of $290.4 million, a 15% year-over-year increase, surpassing analyst expectations by 4.9%, although the full-year guidance fell short, the stock rose 13.1%, indicating market approval of its products.
See More
Israel-Lebanon Ceasefire Boosts Market Sentiment
- Middle East De-escalation: The 10-day ceasefire between Israel and Lebanon has taken effect, leading markets to price in easing tensions, with crude oil prices falling below $100 per barrel and equities rising, indicating investor optimism about future stability.
- Futures Rise: As of 4:00 a.m. ET on Friday, Dow futures rose by 0.3%, S&P 500 futures gained 0.1%, Nasdaq futures remained flat, and Russell 2000 futures increased by 0.2%, reflecting a positive sentiment among investors regarding a potential resolution to the Middle East crisis.
- Netflix Shares Decline: Netflix shares fell nearly 10% in early pre-market trading following a disappointing guidance report, and the news of co-founder Reed Hastings exiting the board in June, although CEO Ted Sarandos noted the company's strong cash position.
- Defense Stocks Favorable: With geopolitical tensions easing, defense-linked companies have gained favor among investors, highlighting ongoing market interest in security and defense sectors amid shifting global dynamics.
See More
FDA Signals Openness to Broader Testosterone Therapy Use
- FDA Policy Shift: The FDA has encouraged sponsors of approved testosterone replacement therapy products to contact the agency about exploring new indications for treating low libido in men with idiopathic hypogonadism, which could open new market opportunities for Hims.
- Hims Platform Expansion: In September 2025, Hims launched personalized doses of compounded enclomiphene to help men restore natural testosterone levels and introduced combination treatment options with tadalafil, which is expected to further drive growth in the male health sector.
- Positive Market Reaction: Hims' stock jumped over 11% on Thursday, marking its fourth consecutive day of gains, reflecting strong market confidence in the company's testosterone therapy potential and indicating a robust trading week ahead.
- Analysts Bullish Outlook: Bank of America raised its price target on Hims, citing the upcoming FDA advisory committee meetings that will review peptide substances for inclusion, suggesting that a favorable outcome could provide new growth opportunities for Hims' existing GLP-1 infrastructure.
See More
US Stocks Close Higher with Chipmakers Rallying
- Market Recovery: On Thursday, the S&P 500 rose by 0.26% and the Nasdaq 100 by 0.49%, reaching new highs, indicating a strong rebound after early losses and reflecting investor confidence in economic recovery.
- Chip Sector Boost: Taiwan Semiconductor Manufacturing Co raised its 2026 revenue forecast, highlighting strong AI demand, which propelled chipmakers' stock prices, particularly benefiting major suppliers to Nvidia and Apple, further enhancing market optimism.
- Oil Price Impact: Despite the stock market gains, crude oil prices surged over 3%, raising concerns about the Middle East situation and limiting the market's upward momentum, illustrating the potential impact of energy prices on the overall economy.
- Mixed Economic Data: Initial jobless claims fell to 207,000, exceeding expectations and indicating labor market strength, but unexpected declines in manufacturing production reflect economic uncertainty, which could influence future monetary policy.
See More
FDA Lifts Restrictions on 12 Peptides, Boosting Hims & Hers
- FDA Policy Change: Health and Human Services Secretary Robert F. Kennedy announced on social media that the FDA will lift the safety risk classification on 12 peptides, allowing compounding pharmacies to manufacture these substances, thereby opening new market opportunities for Hims & Hers.
- Analyst Optimism: Leerink analyst Michael Cherny views this lifting of restrictions as a means for Hims & Hers to fill the growth gap likely arising from its transition to commercial weight loss products, suggesting that while immediate revenue may not materialize, it provides a new avenue for future growth.
- Retail Sentiment Surge: On Stocktwits, retail sentiment around Hims stock jumped from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume increasing by 628%, indicating strong investor confidence in the company's future prospects.
- Positive Market Reaction: Shares of Hims & Hers closed up 12% on Thursday, marking its fourth consecutive day of gains, reflecting the market's positive response to the FDA's policy change and expectations regarding the company's potential in peptide products.
See More
Hims & Hers Health Stock Rises 11.12% on FDA Review News
- Significant Stock Surge: Hims & Hers Health's stock rose by 11.12% to close at $26.98, primarily driven by the FDA's decision to review compounded peptide therapies, indicating strong market confidence in the company's growth potential.
- Surge in Trading Volume: The trading volume reached 74.6 million shares, exceeding the three-month average by 111%, suggesting a notable increase in investor interest and potentially signaling future market trends.
- Optimistic Market Outlook: With the FDA possibly lifting restrictions on 12 peptide drugs, Hims & Hers Health is well-positioned to enter this
See More
Q4 Earnings Overview for Healthcare Tech Stocks
- Hims & Hers Performance: Hims & Hers Health reported revenues of $617.8 million, a 28.4% year-over-year increase, but while the full-year revenue guidance exceeded expectations, the next quarter's guidance fell significantly short, indicating market caution regarding future growth.
- Privia Health Strong Growth: Privia Health achieved revenues of $541.2 million, up 17.4% year-over-year, outperforming analyst expectations by 4.8%, with strong full-year revenue guidance reflecting its competitiveness and market recognition in the healthcare technology sector.
- GoodRx Revenue Decline: GoodRx reported revenues of $194.8 million, down 1.9% year-over-year, exceeding analyst expectations, yet the full-year revenue and EBITDA guidance significantly missed expectations, leading to a 5.7% drop in stock price, highlighting market challenges.
- Tandem Diabetes Stable Performance: Tandem Diabetes reported revenues of $290.4 million, a 15% year-over-year increase, surpassing analyst expectations by 4.9%, although the full-year guidance fell short, the stock rose 13.1%, indicating market approval of its products.
See More
Israel-Lebanon Ceasefire Boosts Market Sentiment
- Middle East De-escalation: The 10-day ceasefire between Israel and Lebanon has taken effect, leading markets to price in easing tensions, with crude oil prices falling below $100 per barrel and equities rising, indicating investor optimism about future stability.
- Futures Rise: As of 4:00 a.m. ET on Friday, Dow futures rose by 0.3%, S&P 500 futures gained 0.1%, Nasdaq futures remained flat, and Russell 2000 futures increased by 0.2%, reflecting a positive sentiment among investors regarding a potential resolution to the Middle East crisis.
- Netflix Shares Decline: Netflix shares fell nearly 10% in early pre-market trading following a disappointing guidance report, and the news of co-founder Reed Hastings exiting the board in June, although CEO Ted Sarandos noted the company's strong cash position.
- Defense Stocks Favorable: With geopolitical tensions easing, defense-linked companies have gained favor among investors, highlighting ongoing market interest in security and defense sectors amid shifting global dynamics.
See More
FDA Signals Openness to Broader Testosterone Therapy Use
- FDA Policy Shift: The FDA has encouraged sponsors of approved testosterone replacement therapy products to contact the agency about exploring new indications for treating low libido in men with idiopathic hypogonadism, which could open new market opportunities for Hims.
- Hims Platform Expansion: In September 2025, Hims launched personalized doses of compounded enclomiphene to help men restore natural testosterone levels and introduced combination treatment options with tadalafil, which is expected to further drive growth in the male health sector.
- Positive Market Reaction: Hims' stock jumped over 11% on Thursday, marking its fourth consecutive day of gains, reflecting strong market confidence in the company's testosterone therapy potential and indicating a robust trading week ahead.
- Analysts Bullish Outlook: Bank of America raised its price target on Hims, citing the upcoming FDA advisory committee meetings that will review peptide substances for inclusion, suggesting that a favorable outcome could provide new growth opportunities for Hims' existing GLP-1 infrastructure.
See More
US Stocks Close Higher with Chipmakers Rallying
- Market Recovery: On Thursday, the S&P 500 rose by 0.26% and the Nasdaq 100 by 0.49%, reaching new highs, indicating a strong rebound after early losses and reflecting investor confidence in economic recovery.
- Chip Sector Boost: Taiwan Semiconductor Manufacturing Co raised its 2026 revenue forecast, highlighting strong AI demand, which propelled chipmakers' stock prices, particularly benefiting major suppliers to Nvidia and Apple, further enhancing market optimism.
- Oil Price Impact: Despite the stock market gains, crude oil prices surged over 3%, raising concerns about the Middle East situation and limiting the market's upward momentum, illustrating the potential impact of energy prices on the overall economy.
- Mixed Economic Data: Initial jobless claims fell to 207,000, exceeding expectations and indicating labor market strength, but unexpected declines in manufacturing production reflect economic uncertainty, which could influence future monetary policy.
See More
FDA Lifts Restrictions on 12 Peptides, Boosting Hims & Hers
- FDA Policy Change: Health and Human Services Secretary Robert F. Kennedy announced on social media that the FDA will lift the safety risk classification on 12 peptides, allowing compounding pharmacies to manufacture these substances, thereby opening new market opportunities for Hims & Hers.
- Analyst Optimism: Leerink analyst Michael Cherny views this lifting of restrictions as a means for Hims & Hers to fill the growth gap likely arising from its transition to commercial weight loss products, suggesting that while immediate revenue may not materialize, it provides a new avenue for future growth.
- Retail Sentiment Surge: On Stocktwits, retail sentiment around Hims stock jumped from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume increasing by 628%, indicating strong investor confidence in the company's future prospects.
- Positive Market Reaction: Shares of Hims & Hers closed up 12% on Thursday, marking its fourth consecutive day of gains, reflecting the market's positive response to the FDA's policy change and expectations regarding the company's potential in peptide products.
See More
Hims & Hers Health Stock Rises 11.12% on FDA Review News
- Significant Stock Surge: Hims & Hers Health's stock rose by 11.12% to close at $26.98, primarily driven by the FDA's decision to review compounded peptide therapies, indicating strong market confidence in the company's growth potential.
- Surge in Trading Volume: The trading volume reached 74.6 million shares, exceeding the three-month average by 111%, suggesting a notable increase in investor interest and potentially signaling future market trends.
- Optimistic Market Outlook: With the FDA possibly lifting restrictions on 12 peptide drugs, Hims & Hers Health is well-positioned to enter this
See More
